LAIYANG, China, May 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company") (which recently changed its name from Genesis Pharmaceuticals Enterprises, Inc.; OTC Bulletin Board: GNPH), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced today that its management will present at the upcoming China Rising Conference hosted by CCG Investor Relations in New York, NY on May 18, 2009.
The date, time and location of Jiangbo Pharmaceuticals, Inc. presentation at the China Rising Conference are:
Date: Monday, May 18, 2009 Time: 9:30 a.m. to 10:00 a.m. Eastern Time Presenter: Ms Elsa Sung, Chief Financial Officer Venue: The Yale Club 50 Vanderbilt Avenue New York, NY 10017 Webcast: http://www.chinarisingconference.com/webcast.html
A replay of the webcast will be available for up to one year following the presentation using the same link.
The China Rising Investment Conference is hosted by CCG Investor Relations and will provide over 250 fund managers and investors access to senior management from a wide range of Chinese growth companies in sectors including consumer staples, agriculture, pharmaceuticals, infrastructure, information technology, advanced materials, capital goods, and alternative energy. The conference will include over 30 US-listed Chinese companies and a number of private companies.
Interested parties and investors can find more information for the conference by visiting CCG's China Rising conference website at: http://www.chinarisingconference.com .
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, and electuary (sticky syrup) form.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact: Company Contact: Ms. Elsa Sung, CFO Jiangbo Pharmaceuticals, Inc. Tel: +1-954-727-8435 Email: email@example.com Website:http://www.jiangbopharma.com/ Investor Relations Contact: Mr. Crocker Coulson, President CCG Investor Relations Tel: +1-646-213-1915 (NY office) Email: firstname.lastname@example.org Graham Reed, Financial Writer Tel: +1-646-213-1907 Email: email@example.com Website:http://www.ccgirasia.com
|SOURCE Jiangbo Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved